2025-02-07 |
Biointron Recognized with 2024 Scientist.com Supplier Performance Recognition Award! |
2025-01-14 |
Week 2, January 2025: Antibodies X PROTACs |
2025-01-13 |
How Biointron Delivers Results in Just 2 Weeks |
2025-01-07 |
January 2025: Antibody Glycoengineering |
2025-01-07 |
Week 1, January 2025: Anti-Malarial Antibodies |
2024-12-24 |
Week 4, December 2024: Evolving Hypotheses in Alzheimer's Research |
2024-12-23 |
Accelerate Antibody Production: Why Top Biotech Firms Choose Biointron |
2024-12-17 |
Week 3, December 2024: Shifting Focus for Infectious Diseases |
2024-12-12 |
Partner with Biointron: Your CRO Solution for Custom Antibody Development |
2024-12-10 |
Week 2, December 2024: Inflammatory Conditions |
2024-12-03 |
Week 1, December 2024: Biparatopic Antibodies |
2024-12-01 |
November 2024: Antibody Reliability |
2024-11-26 |
Week 4, November 2024: The PD-1, PD-L1, and VEGF Train |
2024-11-19 |
Week 3, November 2024: Infant RSV |
2024-11-12 |
Week 2, November 2024: Reliability: Addressing Aggregation, Impurities, and Stability |
2024-11-05 |
Week 1, November 2024: Computationally Designed Antibody Therapeutics |
2024-10-31 |
October 2024: Computationally Designed Antibody Therapeutics |
2024-10-29 |
Week 5, October 2024: Anti-Amyloid Monoclonal Antibodies |
2024-10-22 |
Week 4, October 2024: Further than ADCs? |
2024-10-15 |
Week 3, October 2024: BARDA Funding |
2024-10-08 |
Week 2, October 2024: ADCs in Regulatory Review |
2024-10-04 |
September 2024: Bispecific Antibodies in Oncology |
2024-09-04 |
August 2024: Startup Funding Trends |
2024-08-01 |
July 2024: Paroxysmal nocturnal hemoglobinuria (PNH) |
2024-06-27 |
BIOPLUS-INTERPHEX KOREA 2024 |
2024-06-26 |
The Antibody Engineering & Therapeutics US |
2024-06-26 |
The 3rd Annual Meeting of the Antibody Society of Japan |
2024-06-26 |
Society For Immunotherapy of Cancer (SITC) Annual Meeting 2024 |
2024-06-26 |
PEGS Europe 2024 |
2024-06-26 |
Festival of Biologics 2024 Europe |